In last trading session, Fulcrum Therapeutics Inc (NASDAQ:FULC) saw 0.46 million shares changing hands with its beta currently measuring 2.08. Company’s recent per share price level of $4.15 trading at $0.28 or 7.24% at ring of the bell on the day assigns it a market valuation of $256.55M. That closing price of FULC’s stock is at a discount of -261.45% from its 52-week high price of $15.00 and is indicating a premium of 45.78% from its 52-week low price of $2.25. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.57 million shares which gives us an average trading volume of 1.98 million if we extend that period to 3-months.
For Fulcrum Therapeutics Inc (FULC), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 1.71. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 5 see the stock as a Buy. 1 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.43 in the current quarter.
Fulcrum Therapeutics Inc (NASDAQ:FULC) trade information
Upright in the green during last session for gaining 7.24%, in the last five days FULC remained trading in the green while hitting it’s week-highest on Friday, 11/17/23 when the stock touched $4.15 price level, adding 3.49% to its value on the day. Fulcrum Therapeutics Inc’s shares saw a change of -42.99% in year-to-date performance and have moved 18.57% in past 5-day. Fulcrum Therapeutics Inc (NASDAQ:FULC) showed a performance of 15.92% in past 30-days. Number of shares sold short was 3.95 million shares which calculate 9.47 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $10.21 to the stock, which implies a rise of 59.35% to its current value. Analysts have been projecting $4.50 as a low price target for the stock while placing it at a high target of $16.00. It follows that stock’s current price would drop -285.54% in reaching the projected high whereas dropping to the targeted low would mean a loss of -8.43% for stock’s current value.
Fulcrum Therapeutics Inc (FULC) estimates and forecasts
Statistics highlight that Fulcrum Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 27.69% of value to its shares in past 6 months, showing an annual growth rate of 32.38% while that of industry is 14.80. Apart from that, the company came raising its revenue forecast for fiscal year 2023. The company is estimating its revenue growth to increase by 14.00% in the current quarter and calculating -7.30% decrease in the next quarter. This year revenue growth is estimated to fall -63.40% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $460k for the same. And 5 analysts are in estimates of company making revenue of $400k in the next quarter that will end on Mar 2024. Company posted $685k and $295k of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -32.80% while estimating it to be 35.60% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -17.57% during past 5 years. In 2023, company’s earnings growth rate is likely to be around 32.79% while estimates for its earnings growth in next 5 years are of 6.40%.
Fulcrum Therapeutics Inc is more likely to be releasing its next quarterly report in December and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Fulcrum Therapeutics Inc (NASDAQ:FULC)’s Major holders
Insiders are in possession of 1.58% of company’s total shares while institution are holding 98.73 percent of that, with stock having share float percentage of 100.32%. Investors also watch the number of corporate investors in a company very closely, which is 98.73% institutions for Fulcrum Therapeutics Inc that are currently holding shares of the company. RA Capital Management, L.P. is the top institutional holder at FULC for having 11.61 million shares of worth $38.31 million. And as of Jun 29, 2023, it was holding 18.78% of the company’s outstanding shares.
The second largest institutional holder is RTW Investments LP, which was holding about 6.06 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 9.81% of outstanding shares, having a total worth of $20.01 million.
On the other hand, Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Aug 30, 2023, the former fund manager was holding 1.78 million shares of worth $9.83 million or 2.88% of the total outstanding shares. The later fund manager was in possession of 1.69 million shares on Jun 29, 2023, making its stake of worth around $5.59 million in the company or a holder of 2.74% of company’s stock.